TruSight Tumor 15

TruSight Tumor 15 uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 15 genes that are commonly mutated in solid tumors. It accurately detects low-frequency variants from 20 ng of starting DNA and is optimized for formalin-fixed, paraffin-embedded (FFPE) tumor tissue.

Featuring a rapid workflow that can be easily integrated into lab procedures, this panel offers a single assay for accurate, economical, and rapid analysis of solid tumors.

This TruSight Tumor panel offers:

• Comprehensive workflow: Assess 15 genes with one simple workflow instead of single, iterative gene testing with polymerase chain reaction (PCR)
• Efficient: Rapid turnaround with only 3.5 hours of hands-on time, going from DNA to data in approximately 36 hours
• Relevant gene content for solid tumors: Somatic variants selected from relevant industry guidelines1,2, key opinion leaders3,4, and pharmaceutical research
• Sensitive variant detection from low DNA input: Accurate somatic variant detection of 5% allele frequency using 20 ng DNA from FFPE tissue samples

TruSight Tumor 15 Sample Datasets

3 human reference samples and 5 FFPE-exacted DNA samples from lung, colon, melanoma, and breast tumors were prepared using TruSight Tumor 15. These libraries were sequenced on the MiniSeq System using a high output kit at a 2 x 150 bp read length configuration with dual indexing. The total yield was 7.6 Gb with 94.9% of bases at or above Q30.

TruSight Tumor 15 Data Sheet | PDF(< 1 MB)

Visit    Web Site...